VBLT Vascular Biogenics Ltd. - Ordin

5.60
+0  (0%)
Previous Close 5.60
Open 5.55
Price To book 3.23
Market Cap 150.50M
Shares 26,875,000
Volume 21,488
Short Ratio 3.53
Av. Daily Volume 122,623

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial met primary endpoint. Overall survival data released November 29, 2016 with full data released February 21, 2017.
VB-111
Thyroid cancer
Phase 3 trial to be initiated 2H 2017.
VB-111
Recurrent platinum resistant ovarian cancer
Phase 3 completion of enrollment announced January 6, 2017. Interim analysis due mid 2017. Full data due early 2018.
VB-111
Recurrent glioblastoma (rGBM) cancer
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Ulcerative colitis
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Psoriasis

Latest News

  1. 7:02 am Vascular Biogenics will present full results from its Phase 2 study of VB-111 in patients with advanced, differentiated thyroid cancer; primary endpoint was met
  2. VBL Therapeutics Reports Full Data for VB-111 Monotherapy in Phase 2 Trial for Recurrent Thyroid Cancer
  3. VBL Therapeutics to Present at the 2017 BIO CEO & Investor Conference
  4. VBL Therapeutics Announces Publication of Research on a Potential Novel Immuno-Oncology Target
  5. VBL Therapeutics Provides Year End 2016 Corporate Update
  6. VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study
  7. VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study
  8. How Xenon Pharmaceuticals Inc (XENE) Stacks Up Against Its Peers
  9. VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM
  10. Vascular Biogenics Ltd. :VBLT-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  11. VBL Therapeutics Announces Overall Survival Data for VB-111 Monotherapy in Phase 2 Study for Recurrent Thyroid Cancer
  12. VBL Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29
  13. VBL Therapeutics Announces Third Quarter 2016 Financial Results and Provides Business Update
  14. VBL Therapeutics to Report Third Quarter 2016 Financial Results on November 10
  15. VBL Therapeutics Announces Plans to Establish New Manufacturing Facility
  16. Earnings Estimates Moving Higher for Vascular Biogenics (VBLT): Time to Buy?
  17. 5 Stocks Under $10 That Could Make You a Lot of Money
  18. VBL Therapeutics Announces Second Quarter 2016 Financial Results and Provides Business Update
  19. BioLineRx Names Philip A. Serlin as Chief Executive Officer
  20. BioLineRx Names Philip A. Serlin as Chief Executive Officer